NeoStem, Inc. (NBS) – New Adult Stem Cell Collection Center in Austin to Open April 15, 2010

NEW YORK, April 12 /PRNewswire-Asia-FirstCall/ — NeoStem, Inc. (NYSE Amex: NBS) (“NeoStem” or the “Company”), an international biopharmaceutical company with operations in the U.S. and China, announced the launch of the newest adult stem cell collection center in its network to open in Austin, TX on April 15, 2010. As announced on February 9, 2010, the Company expanded its collection network into the southwestern region of the U.S. with the addition of the physician group at Westlake Orthopaedics Spine & Sports (“Westlake”) located at 5656 Bees Cave Road, k -200 Austin, Texas. NeoStem remains on track to have ten centers in its collection network by the end of 2010.

NeoStem’s Chairman and CEO, Robin Smith, M.D., will participate in the launch of the new center by speaking about the adult stem cell collection process and discussing the potential benefits of early stem cell collection. “We look forward to a productive relationship with the entire Westlake team. As the first to provide adult stem cell banking services to the healthy general public in the U.S., NeoStem is committed to helping individuals pre- donate their healthy cells for personal therapeutic use,” commented Dr. Smith. “We continue to pursue the development of applications of autologous (one’s own) adult stem cells to help in regenerating and repairing damaged cells in the body. The use of autologous stem cells for applications such as wound healing and bone reconstruction removes concerns about immune rejection and is faster and safer than using alleogenic (someone else’s) cells.”

“We are excited about the grand opening of the stem cell collection center in Westlake and, together with NeoStem, look forward to educating our patients about adult stem collection banking and implications for orthopedic treatment,” said Dr. Scott Spann, the founder of Westlake and one of the initial founders of Westlake Hospital. “We remain committed to providing the best patient care in orthopaedic, spine, and sports medicine care. The new stem cell collection center represents an important choice that our patients will now have in planning for a healthy future.”

About NeoStem, Inc.

NeoStem, Inc. is engaged in the development of stem cell-based therapies and building of a network of adult stem cell collection centers in the U.S. and China that are focused on enabling people to donate and store their own (autologous) stem cells for their personal use in times of future medical need. The Company is also the licensee of various stem cell technologies, including a worldwide exclusive license to VSELTM technology which uses very small embryonic-like stem cells, shown to have several physical characteristics that are generally found in embryonic stem cells, and is pursuing the licensing of other technologies for therapeutic use. NeoStem’s majority-controlled Chinese pharmaceutical operation, Suzhou Erye, manufactures and distributes generic antibiotics in China. For more information, please visit: http://www.neostem.com .

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward looking statements include statements herein with respect to the success of new stem cell collection center, the expansion of the collection network and the development of stem cell therapies, about which no assurances can be given. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the “Risk Factors” described in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2010, as well as other periodic filings made with the Securities and Exchange Commission. The Company’s further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.